Navigation Links
Lumeda Enters License Agreement with Roswell Park Comprehensive Cancer Center
Date:6/28/2020

Lumeda Inc. (“Lumeda”), a biophotonics systems company formed to advance photodynamic therapy for treating cancer, today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo, New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device and method for intraoperative photodynamic therapy (IO-PDT), which can be used for treating non-small cell lung cancer (NSCLC).

PDT is an established treatment for a range of cancers but, despite its promise in NSCLC, its broad adoption is hindered by its current treatment delivery mode that is difficult to perform with inconsistent results. The Roswell Park innovation enables a simplified and more effective IO-PDT procedure that could be added to the Standard of Care in NSCLC tumor resection.

“Entering this agreement marks the start of refinement and ultimate introduction of this important lung cancer therapy to the clinic,” according to Trevor MacDougall, one of the founders of Lumeda. “This agreement fosters further collaboration between the world’s leading PDT center and Lumeda’s proven photonics product development team.”

Under the agreement, Lumeda will apply its photonics design and development capabilities to commercialize a complete automated IO-PDT solution.

Photodynamic therapy (PDT) was developed at Roswell Park, which remains a worldwide leader in PDT research and clinical application as a treatment for many types of cancer.

About Roswell Park Comprehensive Cancer Center:
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

About Lumeda:
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit http://www.lumedainc.com.

Read the full story at https://www.prweb.com/releases/lumeda_enters_license_agreement_with_roswell_park_comprehensive_cancer_center/prweb17218726.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Next Generation Protein Sequencing Company Rapid Novor Enters into New Phase of Growth
2. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
3. Bio-Tech Firm PathSensors Enters Fast-Growing Chinese Pathogen Detection Market
4. MMJ International Holdings Enters Cannabis Study Agreement with BioInformatics and Genomics Center (BIG) at the University of Buffalo, New York
5. Research Centers of America Adopts Verified Clinical Trials Biometrics Research Subject Database Registry to Prevent Duplicate Enrollment in Clinical Trials
6. Inspirata to Exhibit at CANCERSCAPE 2017 in Washington DC to Help Community Cancer Centers Better Bridge the Gap Between Pathology and Precision Medicine
7. Northwest Kidney Centers Announces Intention to Grant $15 Million to Jumpstart UW Medicines Center for Dialysis Innovation
8. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
9. Enteris BioPharma Enters Agreement with Sanofi to Develop Investigational Oral Therapeutic for Type 2 Diabetes
10. FireflySci Enters Fiber Optic Probe Market With Several New Offerings
11. Back Pain Centers Of America Calls For Award Submissions For Excellence In Spine Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
(Date:6/11/2020)... ... June 09, 2020 , ... Reducing carbon emissions has been ... the Paris Agreement to stock market dips, ways to reduce CO2 is something we ... their portfolio. Most of the biofuels being produced today are created from recycled cooking ...
(Date:6/2/2020)... ... 01, 2020 , ... As part of its ongoing mission ... world, enterprise security solutions provider bitsIO donated time to help two companies improve ... self-quarantines and shelter-in-place orders, companies are increasingly concerned about the security of their ...
(Date:5/30/2020)... YORK (PRWEB) , ... May 29, 2020 , ... ... of Chief Medical Officer 360°, the first newsletter solely dedicated to the unique ... capture a wide range of perspectives on the responsibilities, problem-solving, best practices and ...
Breaking Biology Technology:
(Date:6/19/2020)... BOSTON (PRWEB) , ... June 16, 2020 , ... The ... Ph.D., is betting that if the stem cell medicine and pharmaceutical industries have easier ... their practice. So, starting July 5 of this year, Independence Day weekend in ...
(Date:6/11/2020)... ... June 08, 2020 , ... Cryo-Cell International’s ... measures to protect workers in the medical field. The face masks will be ... risk their lives every day to provide healthcare to pregnant women. The delivery ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes Mr. ... global perspective to make an impact in a post pandemic world,” said Co-Chairman John ... director of the company. , “The Greffex board is excited to have Neil as ...
Breaking Biology News(10 mins):